Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Inks Coverage Agreement With MultiPlan

NEW YORK (GenomeWeb) – Biocept today announced an agreement to participate in MultiPlan's national primary preferred provider organization and complementary network.

Under the terms of the agreement, patients in MultiPlan's networks will have access to Biocept's liquid biopsy diagnostic services, effective August 1. MultiPlan is a national healthcare organization under contract with almost 900,000 providers, Biocept said in a statement, adding about 68 million consumers access the healthcare cost management firm's networks.

"Our ability to gain agreements with companies such as MultiPlan serves as growing evidence that the healthcare community is recognizing the important role liquid biopsy can play in the treatment of patients with cancer," Biocept President and CEO Michael Nall said in a statement.

San Diego-based Biocept offers blood-based liquid biopsy testing to aid cancer treatment decisions and monitor disease progression.

Earlier this month, Biocept signed similar agreements with Stratose and Galaxy Health Network.